

RESPIRI LIMITED

ASX Announcement
(ASX:RSH)
Date: 26 February 2018

HALF YEAR ENDED DECEMBER 2017 | RESULTS & BUSINESS UPDATE WITH SHAREHOLDERS/INVESTORS

Dear Respiri Shareholders,

We have just announced our Half Year Ended 31 December 2017 results to the market. The company's trend of improving our cash flow position year on year continues with a reduced first half loss of \$782,909 compared with the same half last year of \$1,863,946. The company remains disciplined in our capital management and continues to strictly control its cash burn during this pre-revenue phase. The result reflects the company's increasing ability to optimise the Research and Development Tax Incentive process and ensure payment is more aligned with the dates of the respective R&D activity, including \$753,397 cash received in January 2018 relating to the 30 June 2017 financial year.

The Board is reviewing several proposals to strengthen our capital position, whether it be a formal capital raising or collaboration/joint venture with a potential equity partner(s). Whilst no decision has been made in relation to these proposals as at the date of these financial statements, the directors believe there are reasonable grounds to expect that they will be successful in executing prior to the 30 June 2018 financial year end. The company has a strong track record of accessing capital when it is required to advance our portfolio.

In my CEO update announcement late January 2018, I communicated that I was in the process of conducting a 100 day or 3-month business update and I am pleased to confirm that this is on track for completion by the end of February as committed. As I said then, I am really looking forward to sharing the presentation and engaging with our shareholders and the broader investor community. The anticipated discussions and feedback will provide valuable input as we continue to execute our commercialisation plan and do our best to meet shareholder expectations. With that in mind, we plan to kick things off with a conference call on Monday, March 5th (details below).

Conference call scheduled at 9.15am on 5th March
Number: 1800 062 923
Guest Passcode: 671157359962
Link for Webcast to view presentation will be provide just prior to call

Following the conference call, we are planning a series of face-to-face meetings with shareholders and representatives from the investment community within Australia through the rest of March to maximise access and engage directly with as many of you as possible. This announcement is intended to be short and sharp, hopefully saving my best lines and material for the presentations ahead. The fundamental dynamics of the huge asthma market remain; the gaps and needs to impact the real-life challenges asthma sufferers and carers face is obvious. Respiri's world's first digital wheeze detection technology and asthma management platform can make a real difference.

Mario Gattino
CEO and Director

About Respi Limited (ASX:RSH)

Respi is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun. Respi is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respi in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies.